DE68921918D1 - Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. - Google Patents

Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.

Info

Publication number
DE68921918D1
DE68921918D1 DE68921918T DE68921918T DE68921918D1 DE 68921918 D1 DE68921918 D1 DE 68921918D1 DE 68921918 T DE68921918 T DE 68921918T DE 68921918 T DE68921918 T DE 68921918T DE 68921918 D1 DE68921918 D1 DE 68921918D1
Authority
DE
Germany
Prior art keywords
effectiveness
individual patients
predicting
procedure
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68921918T
Other languages
English (en)
Other versions
DE68921918T2 (de
Inventor
Alan M Gewirtz
Bruno Calabretta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple University of Commonwealth System of Higher Education
Original Assignee
Temple University of Commonwealth System of Higher Education
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple University of Commonwealth System of Higher Education filed Critical Temple University of Commonwealth System of Higher Education
Publication of DE68921918D1 publication Critical patent/DE68921918D1/de
Application granted granted Critical
Publication of DE68921918T2 publication Critical patent/DE68921918T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE68921918T 1988-05-09 1989-05-04 Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten. Expired - Fee Related DE68921918T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19144988A 1988-05-09 1988-05-09

Publications (2)

Publication Number Publication Date
DE68921918D1 true DE68921918D1 (de) 1995-05-04
DE68921918T2 DE68921918T2 (de) 1995-09-07

Family

ID=22705545

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68921918T Expired - Fee Related DE68921918T2 (de) 1988-05-09 1989-05-04 Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.

Country Status (5)

Country Link
US (1) US5427916A (de)
EP (1) EP0341904B1 (de)
JP (1) JPH0636759B2 (de)
AT (1) ATE120497T1 (de)
DE (1) DE68921918T2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0550592B1 (de) * 1990-09-24 1997-01-15 BRENT, Roger Überprüfungsteste
DE69214243T2 (de) * 1991-09-23 1997-02-06 Pfizer Verfahren für die Detektion von spezifische mRNS und DNS in Zellen
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
AU685058B2 (en) * 1992-06-16 1998-01-15 Selective Genetics, Inc. Recombinant production of saporin-containing proteins
CA2136439A1 (en) * 1992-06-18 1994-01-06 Michael Philip Nova Process for detection of neoplastic disease
GB9220777D0 (en) * 1992-10-02 1992-11-18 Univ Leicester Oligonucleotide probes
US5763198A (en) * 1994-07-22 1998-06-09 Sugen, Inc. Screening assays for compounds
JP2000510330A (ja) 1996-04-05 2000-08-15 トーマス・ジェファーソン・ユニバーシティ 癌の診断および予後のための方法
US5955269A (en) * 1996-06-20 1999-09-21 Rutgers, The State University Of New Jersey Methods of screening foods for nutraceuticals
WO2001023615A1 (en) * 1999-09-29 2001-04-05 Lifespan Biosciences, Inc. Anti-aging nucleic acid and protein targets
WO2002039121A2 (en) * 2000-11-03 2002-05-16 Board Of Regents, The University Of Texas System Methods for detecting the efficacy of anticancer treatments
EP2295604B1 (de) 2004-02-09 2015-04-08 Thomas Jefferson University Krebsdiagnose und Behandlung durch microRNA, die sich in der Nähe von Krebs-verbindenen Chromosom-Merkmale befinden
US7012200B2 (en) * 2004-02-13 2006-03-14 Sonion Roskilde A/S Integrated volume control and switch assembly
US20060019972A1 (en) * 2004-04-27 2006-01-26 California Institute Of Technology Methods of treating cancer by inhibiting histone gene expression
CN101426930A (zh) * 2004-05-25 2009-05-06 日立化成工业株式会社 检测癌症易感性的方法
EP1802776B1 (de) * 2004-10-20 2013-01-02 Hitachi Chemical Company, Ltd. Verfahren zur anpassung der arzneimittelverabreichung durch quantifizierung von mrna
WO2006086681A2 (en) * 2005-02-09 2006-08-17 Beth Israel Deaconess Medical Center, Inc. Methods of inhibiting smooth muscle cell migration and proliferation
ATE512234T1 (de) * 2005-04-28 2011-06-15 Hitachi Chemical Res Ct Inc Ex-vivo-genexpression in vollblut als modell für die beurteilung von individueller variation gegenüber nahrungszusätzen
US20090270479A1 (en) * 2005-07-12 2009-10-29 Antonio Giordano Genetic and Epigenetic Alterations In the Diagnosis and Treatment of Cancer
EP1937280B1 (de) 2005-09-12 2014-08-27 The Ohio State University Research Foundation Zusammensetzungen zur Therapie von Bcl2-assoziierten Tumoren
AU2007205257B2 (en) 2006-01-05 2013-07-25 The Ohio State University Research Foundation MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors
CN102943108B (zh) 2006-01-05 2014-05-21 俄亥俄州立大学研究基金会 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物
EP2468899B1 (de) 2006-01-05 2015-03-11 The Ohio State University Research Foundation Verfahren auf Mikro-RNA-Basis zur Diagnose von Magenkrebs
EP2522747A1 (de) 2006-03-02 2012-11-14 The Ohio State University Mikro-RNA-Expressionsprofil im Zusammenhang mit Bauchspeicheldrüsenkrebs
AU2007227423B2 (en) 2006-03-20 2013-11-07 The Ohio State University Research Foundation MicroRNA fingerprints during human megakaryocytopoiesis
US8268566B2 (en) * 2006-04-07 2012-09-18 Hitachi Chemical Research Center, Inc. Enhanced FC receptor-mediated tumor necrosis factor superfamily MRNA expression in peripheral blood leukocytes in patients with rheumatoid arthritis
US20090298071A1 (en) * 2006-05-08 2009-12-03 Masato Mitsuhashi Method for testing drug sensitivity in solid tumors by quantifying mrna expression in thinly-sliced tumor tissue
WO2007134142A2 (en) * 2006-05-11 2007-11-22 University College Dublin Methods and compositions for identifying and using p21-regulated proteins
EP2369017B8 (de) 2006-07-13 2014-03-12 The Ohio State University Research Foundation Verfahren und Zusammensetzungen auf Mikro-RNA-Basis zur Diagnose und Behandlung von Krankheiten im Zusammenhang mit dem Dickdarm
WO2008115387A2 (en) * 2007-03-15 2008-09-25 University Hospitals Of Cleveland Screening, diagnosing, treating and prognosis of pathophysiologic states by rna regulation
ES2537349T3 (es) 2007-06-08 2015-06-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Métodos para determinar un subtipo de carcinoma hepatocelular
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
WO2009018303A2 (en) 2007-07-31 2009-02-05 The Ohio State University Research Foundation Methods for reverting methylation by targeting dnmt3a and dnmt3b
CN103866008B (zh) 2007-08-03 2016-06-29 俄亥俄州立大学研究基金会 编码ncrna的超保守区域
CA2696887C (en) 2007-08-22 2016-06-28 The Ohio State University Research Foundation Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias
EP2775001B1 (de) 2007-09-06 2016-03-09 The Ohio State University Research Foundation MikroRNA-Signaturen in menschlichem Ovarialkarzinom
US20100285471A1 (en) 2007-10-11 2010-11-11 The Ohio State University Research Foundation Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas
US20090215064A1 (en) * 2008-02-27 2009-08-27 Hitachi Chemical Co., Ltd. Quantitative assessment of individual cancer susceptibility by measuring dna damage-induced mrna in whole blood
US9181315B2 (en) 2009-01-08 2015-11-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US8492133B2 (en) 2009-01-20 2013-07-23 Ramot At Tel Aviv University, Ltd. MIR-21 promoter driven targeted cancer therapy
WO2010105096A2 (en) 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
WO2010149666A1 (en) 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2473628A1 (de) 2009-08-31 2012-07-11 Alcedo Biotech GmbH Mirna-basierte verfahren und zusammensetzungen zur diagnose, prognose und behandlung von tumor mit chromosomaler neuanordnung
WO2011029639A2 (en) 2009-09-08 2011-03-17 Medexis S.A. Compounds and methods for treating neoplasia
TW201132813A (en) 2010-03-03 2011-10-01 Koo Foundation Sun Yat Sen Cancer Ct Methods for classifying and treating breast cancers
WO2012013816A1 (en) 2010-07-30 2012-02-02 Medexis S.A. Compounds and methods for treating neoplasia
CA2807244A1 (en) 2010-08-27 2012-03-01 University Of Zurich A novel diagnostic and therapeutic target in inflammatory and/or cardiovascular diseases
EP2546358A1 (de) 2011-07-15 2013-01-16 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Reagenzien zur effizienten Steuerung des HIV-Fortschritts
AU2012323924A1 (en) 2011-10-14 2014-05-29 The Ohio State University Methods and materials related to ovarian cancer
WO2014145254A2 (en) 2013-03-15 2014-09-18 Sutter West Bay Hospitals Falz for use as a target for therapies to treat cancer
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
DE112016003948T5 (de) 2015-08-31 2018-05-09 City Of Sapporo Molekulare verfahren zum beurteilen einer urothelialen erkrankung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI76119C (fi) * 1986-02-27 1988-09-09 Orion Yhtymae Oy Kvantitativ bestaemning av nukleinsyramolekyler och reagensfoerpackning som anvaends vid foerfarandet.
NO881560L (no) * 1987-05-05 1988-11-07 Hope City Fremgangsmaate for detektering av begynnende resistens motterapeutiske midler i kreftpasienter.

Also Published As

Publication number Publication date
EP0341904A3 (de) 1991-11-27
EP0341904A2 (de) 1989-11-15
ATE120497T1 (de) 1995-04-15
DE68921918T2 (de) 1995-09-07
US5427916A (en) 1995-06-27
EP0341904B1 (de) 1995-03-29
JPH0213400A (ja) 1990-01-17
JPH0636759B2 (ja) 1994-05-18

Similar Documents

Publication Publication Date Title
DE68921918D1 (de) Verfahren zur Voraussage der Wirksamkeit einer antineoplastichen Behandlung bei einzelnen Patienten.
ATE360989T1 (de) Präzise wirksamkeitsbestimmungsmethode für wirkstoffe einschliesslich chemotherapeutika
IE46078L (en) Apparatus for treating living tissues and/or cells by¹electromagnetically inducing voltage and current pulses¹within the tissue and/or cells.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE3869490D1 (de) Verfahren zur elektrochemischen behandlung von stoffen.
PT87086A (pt) Active specific immune suppression
DE3782917D1 (de) Verfahren zum herabsetzen des gehalts an rueckstaendigen aldehyden in implantierbaren bioprosthetischen geweben.
DE68917268T3 (de) Die Verwendung von ausgewählten amphiphilen Copolymeren in der Behandlung von Leder.
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
DE3880118D1 (de) Verwendung eines mittels in form von mikrokapseln zur schabenbekaempfung.
DE3874019D1 (de) Verfahren zur konservierung von transplantierbaren, in vitro kultivierten epithelgeweben.
DE3785602D1 (de) Verwendung von a-, b- und c-prostaglandinen und deren derivaten zur behandlung von augen-hypertension und glaukom.
ES2110091T3 (es) Terapia tumoricida de efecto de alerta.
DE3869230D1 (de) Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin.
NO882854L (no) Korreksjon med dobbeltraadet rna av avvikende metabolske spor forbundet med ukontrollerte vekstsykluser for tumorceller og virus.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
NO884061D0 (no) Fremgangsmaate for regulering av surhetsgraden i et elektrolytisk bad.
DE3884777D1 (de) Verfahren zur Herstellung von Pregneno-Oxazolinen.
DK0782452T3 (da) Cellevækstregulator
JPS51128474A (en) Process for treating of microbial cells
ATE104147T1 (de) Verwendung von inositol-triphosphat zur behandlung von metallvergiftung.
ATE88090T1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
NO162739C (no) Fremgangsmaate og innretning for kvantitativ besemmelse avhemoglobinnivaaet i en biologisk proeve.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
ES499967A0 (es) Un dispositivo de tratamiento corporal electromagnetico parala modificacion quirurgicamente no invasiva del comporta- miento de desarrollo,reparacion y mantenimiento de celulas ytejidos vivos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee